132 related articles for article (PubMed ID: 9736064)
1. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange.
Romano JG; Rotta FT; Potter P; Rosenfeld V; Santibanez R; Rocha B; Bradley WG
Muscle Nerve; 1998 Oct; 21(10):1327-30. PubMed ID: 9736064
[TBL] [Abstract][Full Text] [Related]
2. High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome.
Ravasio A; Pasquinelli M; Currò Dossi B; Neri W; Guidi C; Gessaroli M; Rasi F; Fabbri R; Mazzini G; Rebucci GG
Ital J Neurol Sci; 1995 Oct; 16(7):487-92. PubMed ID: 8749707
[TBL] [Abstract][Full Text] [Related]
3. [A case of Guillain-Barré syndrome treated with plasma exchange and intravenous high-dose immune globulin].
Imai N; Miyata K; Terayama Y; Ishihara N
Rinsho Shinkeigaku; 1997 Jun; 37(6):520-2. PubMed ID: 9366182
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
[TBL] [Abstract][Full Text] [Related]
5. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA
Ther Apher; 1997 May; 1(2):129-30. PubMed ID: 10225757
[TBL] [Abstract][Full Text] [Related]
6. Plasma exchange and i.v.-immunoglobulins: new approaches to the treatment of Guillain-Barre' syndrome.
Fasanaro AM; Pizza V; Stella L
Acta Neurol (Napoli); 1992; 14(4-6):369-80. PubMed ID: 1293980
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin.
Haupt WF; Rosenow F; van der Ven C; Borberg H; Pawlik G
J Neurol Sci; 1996 May; 137(2):145-9. PubMed ID: 8782169
[TBL] [Abstract][Full Text] [Related]
8. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities.
Dawson WB; Phillips LH
Clin Neuropharmacol; 1995 Oct; 18(5):377-90. PubMed ID: 8665552
[TBL] [Abstract][Full Text] [Related]
9. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
[TBL] [Abstract][Full Text] [Related]
10. Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome?
Weinstein R
J Clin Apher; 1995; 10(3):150-7. PubMed ID: 8582898
[No Abstract] [Full Text] [Related]
11. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.
van der Meché FG; Schmitz PI
N Engl J Med; 1992 Apr; 326(17):1123-9. PubMed ID: 1552913
[TBL] [Abstract][Full Text] [Related]
12. [Value of intravenous immunoglobulins. A case of Guillain-Barré syndrome].
Hidou M; Olivier J; Vivant JF
Rev Neurol (Paris); 1992; 148(11):706-8. PubMed ID: 1303562
[TBL] [Abstract][Full Text] [Related]
13. No increased relapse frequency in acute Guillain-Barré syndrome after plasma exchange.
Ernerudh J; Osterberg A; Berlin G
Acta Neurol Scand; 1990 Oct; 82(4):284-6. PubMed ID: 2270758
[TBL] [Abstract][Full Text] [Related]
14. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome.
Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K
Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353
[TBL] [Abstract][Full Text] [Related]
15. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
Kleyweg RP; van der Meché FG
J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
[TBL] [Abstract][Full Text] [Related]
16. High-dose intravenous immune globulin in the management of severe Guillain-Barre syndrome.
Baskin E; Turkay S; Icagasioglu D; Tanzer F; Cevit O
Turk J Pediatr; 1996; 38(1):119-23. PubMed ID: 8819632
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin.
Haupt WF; Rosenow F; van der Ven C; Borberg H; Pawlik G
Ther Apher; 1997 Feb; 1(1):55-7. PubMed ID: 10225782
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome.
Ng KK; Howard RS; Hirsch NP; Miller DH
Neurology; 1993 Dec; 43(12):2729; author reply 2730-1. PubMed ID: 8255495
[No Abstract] [Full Text] [Related]
19. [Immunoglobulins or plasma exchange? Guillain-Barré syndrome: indications for plasma exchange and immunoglobulins].
Raphaël JC; Chevret S; Jars-Guincestre MC; Chastang C; Gajdos P
Ann Med Interne (Paris); 1993; 144(8):526-31. PubMed ID: 8179242
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
Visser LH; van der Meché FG; Meulstee J; van Doorn PA
J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
